骨髓纤维化与血栓栓塞的关联:一项基于人群的回顾性队列研究
该研究基于以色列最大医疗机构的电子病历,纳入642例骨髓纤维化患者和2568例匹配对照,发现骨髓纤维化独立增加静脉血栓栓塞风险(HR 6.88,95%CI 2.02-23.45),但不增加动脉血栓栓塞风险(HR 0.94,95%CI 0.49-1.77)。非典型部位静脉血栓栓塞几乎仅见于骨髓纤维化患者,且多发生于诊断前后。
要点
- 骨髓纤维化患者静脉血栓栓塞风险显著增高约7倍。
- 动脉血栓栓塞风险未见显著增加。
- 非典型部位静脉血栓栓塞(如布加综合征、肠系膜静脉血栓)多见于骨髓纤维化诊断前后。
核心结论
- 骨髓纤维化与静脉血栓栓塞风险增加相关,但与动脉血栓栓塞风险无关。
- 非典型部位静脉血栓栓塞在骨髓纤维化患者中更常见,且多发生于诊断后短期内。
研究设计与样本
- 基于人群的回顾性队列研究,从以色列最大医疗机构的电子病历中于2007年1月1日识别1 469 790名无骨髓纤维化诊断的成人,随访至2016年12月31日。
- 共纳入642例骨髓纤维化患者,按年龄、性别、宗教认同和索引日期以1:4匹配2568例对照,随访至2017年12月31日。
主要发现
- 倾向性评分调整后的静脉血栓栓塞风险比(HR)为6.88(95%CI 2.02-23.45)。
- 动脉血栓栓塞的HR为0.94(95%CI 0.49-1.77)。
- 非典型部位静脉血栓栓塞几乎仅见于骨髓纤维化患者:布加综合征4例 vs 0例,肠系膜静脉血栓2例 vs 1例。
- JAK2抑制剂芦可替尼治疗与静脉血栓栓塞风险无显著关联(HR 0.97,95%CI 0.30-3.12),与动脉血栓栓塞风险亦无显著关联(HR 1.68,95%CI 0.78-3.62)。
临床怎么用
- 对骨髓纤维化患者应警惕静脉血栓栓塞风险,尤其在诊断前后。
- 非典型部位血栓栓塞事件应考虑骨髓纤维化的可能。
- 芦可替尼治疗未显示增加或降低血栓栓塞风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of thromboembolism in myelofibrosis remains incompletely understood. OBJECTIVES: To examine the association between myelofibrosis and each of venous and arterial thromboembolism. METHODS: A cohort of 1 469 790 adults without a diagnosis of myelofibrosis was identified on 1 January 2007, from the electronic medical records of the largest health-care provider in Israel. Participants were followed until 31 December 2016 for the occurrence of myelofibrosis. Four randomly selected controls (without myelofibrosis) were matched to each case of myelofibrosis on age, sex, religious identification, and index date. The two groups were followed from the index date until 31 December 2017 for the occurrence of venous and arterial thromboembolism. RESULTS: The study included 642 patients with myelofibrosis and 2568 matched controls. Myelofibrosis was independently associated with increased risk of venous thromboembolism but not with arterial thromboembolism. The propensity score adjusted hazard ratios (HRs) were 6.88 (95% confidence interval [CI], 2.02-23.45) for venous thromboembolism, and 0.94 (0.49-1.77) for arterial thromboembolism. Atypical sites of venous thromboembolism occurred almost exclusively in patients with myelofibrosis (four events of Budd Chiari versus none, and two mesenteric vein thrombosis events versus one) and were more likely to occur around the time of myelofibrosis diagnosis. No significant association was found between JAK2 inhibitor treatment (ruxolitinib) and the risk of venous HR 0.97 (0.30-3.12) or arterial thromboembolism 1.68 (0.78-3.62). CONCLUSIONS: Myelofibrosis is associated with increased risk of venous thromboembolism but not of arterial thromboembolism. Atypical sites of venous thromboembolism are more frequent in myelofibrosis and are more likely to occur shortly after diagnosis.
引用
- Saliba W, Mishchenko E, Cohen S, et al. Association between myelofibrosis and thromboembolism: A population-based retrospective cohort study. J Thromb Haemost. 2020. PMID: 32017387. doi:10.1111/jth.14754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。